Madrigal's Cholesterol Drug Succeeds in Mid-Stage Trial Post author:Sam Post published:February 7, 2018 Post category:BioPharma MGL-3196 was well-tolerated with primarily mild and some moderate AEs. Source: BioSpace You Might Also Like With a Collaboration Deal in Place with Merck, Cue Biopharma Plans $60 Million IPO December 18, 2017 Why Amgen Needs an Acquisition to Keep Up with Immuno-Oncology Competitors July 9, 2017 XW Laboratories Inc. Secures Over $17M Series B Financing Led By And September 19, 2017
